Patents by Inventor Giuliana Salvatore

Giuliana Salvatore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
    Patent number: 8809502
    Abstract: Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: August 19, 2014
    Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Ira Pastan, Giuliana Salvatore, Richard Beers, Robert Kreitman
  • MUTATED ANTI-CD22 ANTIBODIES WITH INCREASED AFFINITY TO CD22-EXPRESSING LEUKEMIA CELLS
    Publication number: 20120258106
    Abstract: Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.
    Type: Application
    Filed: April 3, 2012
    Publication date: October 11, 2012
    Applicants: Health and Human Services
    Inventors: Ira H Pastan, Giuliana Salvatore, Richard Beers, Robert J. Kreitman
  • MUTATED ANTI-CD22 ANTIBODIES WITH INCREASED AFFINITY TO CD22-EXPRESSING LEUKEMIA CELLS
    Publication number: 20110065185
    Abstract: Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.
    Type: Application
    Filed: July 29, 2010
    Publication date: March 17, 2011
    Applicant: The Government of U.S.A as represented by the Secretary of the Dept of Health and Human Services
    Inventors: Ira H. Pastan, Giuliana Salvatore, Richard Beers, Robert J. Kreitman
  • Mutated Anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
    Patent number: 7777019
    Abstract: Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.
    Type: Grant
    Filed: February 13, 2008
    Date of Patent: August 17, 2010
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ira Pastan, Giuliana Salvatore, Richard Beers, Robert J. Kreitman
  • Mutated Anti-CD22 Antibodies With Increased Affinity To CD22-Expressing Leukemia Cells
    Publication number: 20090004734
    Abstract: Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.
    Type: Application
    Filed: February 13, 2008
    Publication date: January 1, 2009
    Applicants: HEALTH AND HUMAN SERVICES
    Inventors: Ira H. Pastan, Giuliana Salvatore, Richard Beers, Robert J. Kreitman
  • Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
    Patent number: 7355012
    Abstract: Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.
    Type: Grant
    Filed: September 25, 2002
    Date of Patent: April 8, 2008
    Assignee: United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Ira H. Pastan, Giuliana Salvatore, Richard Beers, Robert J. Kreitman
  • Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
    Publication number: 20050118182
    Abstract: Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.
    Type: Application
    Filed: September 25, 2002
    Publication date: June 2, 2005
    Inventors: Ira Pastan, Giuliana Salvatore, Richard Beers, Robert Kreitman